LifeSplice Pharma Competitors and Similar CompaniesClear all
LifeSplice Pharma's competitors and similar companies include Aerie Pharmaceuticals, Alnylam and Sorrento Therapeutics.
 LifeSplice Pharma LifeSplice Pharma is a biotechnology company that develops products for the treatment of neurological and non-neurological diseases. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date 2011 | Founding Date 2005 | Founding Date 2002 | Founding Date 2006 |
Type | Type Private | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Malvern, US HQ | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations San Diego, US HQ San Diego, US | |
Employees | Employees 2 | Employees 3808% increase | Employees 1,32324% increase | Employees 31019% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 722.2 m | Valuation ($) 36.5 b | Valuation ($) 1.5 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) | Cost of goods $677.2m (FY, 2025) | Cost of goods N/A |
Net income | Net income N/A | Net income ($74.8m) (FY, 2021) | Net income $313.7m (FY, 2025) | Net income ($577.8m) (FY, 2022) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 388.6m | Total funding raised $ 1.5b | Total funding raised $ 42.6m |
For sources of this data, please see the company profile
View Company Profiles
Aerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company